Wilkins Investment Counsel Inc. Has $18.86 Million Position in Medtronic PLC $MDT

Key Points

• Wilkins Investment Counsel trimmed its Medtronic stake by 7.7% in Q4, selling 16,331 shares to hold 196,350 shares valued at about $18.86 million, making MDT its 11th-largest position (~2.7% of the portfolio).
• Several large institutions materially increased positions—Barclays (+104.6%), Schroder (+78.3%), Wellington (+35.3%) and SG Americas (+2,297.7% in Q4)—with institutional investors now owning about 82.06% of the stock.
• Medtronic beat Q results slightly (EPS $1.36 vs. $1.34 est.) with revenue of $9.02B (+5.8% y/y), set FY2026 guidance of $5.62–$5.66 EPS, and pays a quarterly dividend of $0.71 (≈3.5% yield).

Wilkins Investment Counsel Inc. reduced its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 7.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 196,350 shares of the medical technology company's stock after selling 16,331 shares during the period. Medtronic makes up about 2.7% of Wilkins Investment Counsel Inc.'s investment portfolio, making the stock its 11th biggest position. Wilkins Investment Counsel Inc.'s holdings in Medtronic were worth $18,861,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Barclays PLC increased its stake in Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock valued at $650,604,000 after purchasing an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group increased its stake in Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company's stock valued at $717,143,000 after purchasing an additional 3,307,211 shares in the last quarter. Guinness Asset Management LTD bought a new stake in Medtronic in the third quarter valued at approximately $275,556,000. Wellington Management Group LLP increased its position in shares of Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after acquiring an additional 2,658,981 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Medtronic by 2,297.7% during the fourth quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company's stock worth $241,179,000 after acquiring an additional 2,406,000 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

Medtronic Stock Performance

NYSE MDT opened at $80.02 on Friday. The firm has a 50-day moving average of $88.44 and a 200-day moving average of $94.81. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market cap of $102.74 billion, a PE ratio of 22.29, a P/E/G ratio of 2.08 and a beta of 0.62. Medtronic PLC has a 52-week low of $78.91 and a 52-week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. During the same quarter last year, the company posted $1.38 EPS. Medtronic's quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic's dividend payout ratio (DPR) is currently 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. CICC Research assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They set an "outperform" rating for the company. Needham & Company LLC reissued a "buy" rating and set a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Robert W. Baird increased their price objective on shares of Medtronic from $92.00 to $93.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Jefferies Financial Group reissued a "hold" rating and set a $95.00 price objective on shares of Medtronic in a research report on Thursday, April 23rd. Finally, Leerink Partners reissued an "outperform" rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $107.80.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.